Joseph Pearlberg

3.5k total citations
34 papers, 2.3k citations indexed

About

Joseph Pearlberg is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joseph Pearlberg has authored 34 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 15 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joseph Pearlberg's work include HER2/EGFR in Cancer Research (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Joseph Pearlberg is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Joseph Pearlberg collaborates with scholars based in United States, France and Germany. Joseph Pearlberg's co-authors include Steven E. Hyman, Michael J. Comb, H. M. Goodman, Jeffrey A. Engelman, Bruce E. Johnson, Pasi A. Jänne, Toru Mukohara, Lewis C. Cantley, Mark Ptashne and M. Elizabeth Ross and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Joseph Pearlberg

34 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph Pearlberg United States 20 1.5k 740 487 340 272 34 2.3k
Angabin Matin United States 20 1.5k 1.0× 587 0.8× 419 0.9× 98 0.3× 772 2.8× 43 2.6k
Zhaohai Yang United States 25 850 0.6× 1.1k 1.5× 169 0.3× 392 1.2× 309 1.1× 78 2.9k
Su Yang China 26 1.4k 0.9× 550 0.7× 155 0.3× 510 1.5× 290 1.1× 93 2.4k
Marcus Schuermann Germany 24 2.2k 1.5× 626 0.8× 133 0.3× 343 1.0× 440 1.6× 43 3.0k
Saïd Akli United States 24 1.0k 0.7× 509 0.7× 194 0.4× 287 0.8× 562 2.1× 40 1.8k
Judy M. Coulson United Kingdom 26 1.8k 1.2× 581 0.8× 215 0.4× 159 0.5× 293 1.1× 66 2.4k
Bao Hoang United States 26 1.2k 0.8× 534 0.7× 100 0.2× 254 0.7× 90 0.3× 40 2.0k
Edwin J. Ostrin United States 24 1.3k 0.8× 586 0.8× 586 1.2× 140 0.4× 90 0.3× 53 2.3k
Gianluca Civenni Switzerland 26 1.7k 1.1× 807 1.1× 281 0.6× 369 1.1× 108 0.4× 57 2.7k
Alain Eychène France 32 2.2k 1.4× 798 1.1× 132 0.3× 234 0.7× 246 0.9× 55 3.0k

Countries citing papers authored by Joseph Pearlberg

Since Specialization
Citations

This map shows the geographic impact of Joseph Pearlberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Pearlberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Pearlberg more than expected).

Fields of papers citing papers by Joseph Pearlberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Pearlberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Pearlberg. The network helps show where Joseph Pearlberg may publish in the future.

Co-authorship network of co-authors of Joseph Pearlberg

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Pearlberg. A scholar is included among the top collaborators of Joseph Pearlberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Pearlberg. Joseph Pearlberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tolcher, Anthony W., David S. Hong, Ryan J. Sullivan, et al.. (2017). Abstract CT089: IPI-549-01 - A Phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors. Cancer Research. 77(13_Supplement). CT089–CT089. 10 indexed citations
2.
Abramson, Vandana G., Jeffrey G. Supko, Tarah J. Ballinger, et al.. (2016). Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. Clinical Cancer Research. 23(14). 3520–3528. 23 indexed citations
3.
Bensch, Frederike, Andor W.J.M. Glaudemans, Thijs H. Oude Munnink, et al.. (2015). TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET. Journal of Nuclear Medicine. 56(9). 1310–1314. 79 indexed citations
4.
Cleary, James M., Autumn J. McRee, Bert H. O’Neil, et al.. (2014). A phase 1 study of MM-121 (a fully human monoclonal antibody targeting the epidermal growth factor receptor family member ErbB3) in combination with cetuximab and irinotecan in patients with advanced cancers.. Journal of Clinical Oncology. 32(15_suppl). 3076–3076. 10 indexed citations
5.
MacBeath, Gavin, Éric Pujade-Lauraine, M.A. Higgins, et al.. (2014). A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers. Annals of Oncology. 25. iv82–iv82. 6 indexed citations
6.
Arnedos, Mónica, Crystal S. Denlinger, Wael A. Harb, et al.. (2013). A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2609–2609. 8 indexed citations
7.
Sequist, Lecia V., Manuel Modiano, Olivier Rixe, et al.. (2012). Targeting EGFR and ERBB3 in lung cancer patients: Clinical outcomes in a phase I trial of MM-121 in combination with erlotinib.. Journal of Clinical Oncology. 30(15_suppl). 7556–7556. 6 indexed citations
8.
Park, Jae-Hong, Lihua Zou, Yanhui Hu, et al.. (2011). High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proceedings of the National Academy of Sciences. 108(5). 2058–2063. 88 indexed citations
9.
Foley, Jonathan E., Morgan L. Maeder, Joseph Pearlberg, et al.. (2009). Targeted mutagenesis in zebrafish using customized zinc-finger nucleases. Nature Protocols. 4(12). 1855–1868. 106 indexed citations
10.
Rolfs, Andreas, Yanhui Hu, Lars Ebert, et al.. (2008). A Biomedically Enriched Collection of 7000 Human ORF Clones. PLoS ONE. 3(1). e1528–e1528. 20 indexed citations
11.
Baldwin, Amy, Wenliang Li, Miranda Grace, et al.. (2008). Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells. Proceedings of the National Academy of Sciences. 105(43). 16478–16483. 36 indexed citations
12.
Mukohara, Toru, Jeffrey A. Engelman, Nasser H. Hanna, et al.. (2005). Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations. JNCI Journal of the National Cancer Institute. 97(16). 1185–1194. 256 indexed citations
13.
Pearlberg, Joseph, Sébastien Degot, Wilson O. Endege, et al.. (2005). Screens Using RNAi and cDNA Expression as Surrogates for Genetics in Mammalian Tissue Culture Cells. Cold Spring Harbor Symposia on Quantitative Biology. 70(0). 449–459. 22 indexed citations
14.
Engelman, Jeffrey A., Pasi A. Jänne, Craig H. Mermel, et al.. (2005). ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proceedings of the National Academy of Sciences. 102(10). 3788–3793. 404 indexed citations
15.
Mukohara, Toru, J. A. Engelman, Joseph Pearlberg, et al.. (2005). O-009 Differential effects of gefitinib and cetuximab on EGFR mutant non-small cell lung cancers (NSCLC) cell lines. Lung Cancer. 49. S7–S7. 1 indexed citations
16.
Pearlberg, Joseph & Joshua LaBaer. (2004). Protein expression clone repositories for functional proteomics. Current Opinion in Chemical Biology. 8(1). 98–102. 10 indexed citations
17.
Wang, David, Joseph Pearlberg, Yu‐Tsueng Liu, & Don Ganem. (2001). Deleterious Effects of Hepatitis Delta Virus Replication on Host Cell Proliferation. Journal of Virology. 75(8). 3600–3604. 22 indexed citations
18.
Himmelfarb, Howard J., et al.. (1990). GAL11P: A yeast mutation that potentiates the effect of weak GAL4-derived activators. Cell. 63(6). 1299–1309. 136 indexed citations
19.
Hyman, Steven E., Michael J. Comb, Joseph Pearlberg, & Howard M. Goodman. (1989). An AP-2 Element Acts Synergistically with the Cyclic AMP- and Phorbol Ester-Inducible Enhancer of the Human Proenkephalin Gene. Molecular and Cellular Biology. 9(1). 321–324. 40 indexed citations
20.
Hyman, Steven E., Michael J. Comb, Young-Sun Lin, et al.. (1988). A Common trans -Acting Factor Is Involved in Transcriptional Regulation of Neurotransmitter Genes by Cyclic AMP. Molecular and Cellular Biology. 8(10). 4225–4233. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angabin Matin Breakdown of academic impact, for papers by Zhaohai Yang Breakdown of academic impact, for papers by Su Yang Breakdown of academic impact, for papers by Marcus Schuermann Breakdown of academic impact, for papers by Saïd Akli Breakdown of academic impact, for papers by Judy M. Coulson Breakdown of academic impact, for papers by Bao Hoang Breakdown of academic impact, for papers by Edwin J. Ostrin Breakdown of academic impact, for papers by Gianluca Civenni Breakdown of academic impact, for papers by Alain Eychène
Rankless by CCL
2026